In this special crossover podcast episode, Tuesday Night IBS hosts Jeffrey Roberts, MSEd, BSc, Erica Dermer and Kate Scarlata, MPH, RDN, are joined live by William Chey, MD, and Amanda Lynett, MS, RDN, at FOOD the Main Course Conference in Ann Arbor, MI.

• Intro :02
• About Scarlata :30
• About Chey 1:07
• About Lynett 1:49
• Chey, what are your goals for this year’s FOOD the Main Course Conference? 2:58
• How do you feel that mechanisms of diet are affecting microbiomes? 5:37
• Amanda, what have you learned over the years as you have put together this conference, and how do you think this experience has shaped a more well-rounded program for clinicians? 8:23
• What are you personally going to take away from the conference this year? 11:17
• A discussion on peer-to-peer interactions, the spirit of collaborative care, and what each provider is bringing to the table. 12:22
• Kate, tell us about why you come back to this conference every year. 17:32
• What challenges did you overcome to move the needle forward in diet and GI conditions? 19:14
• Chey, can you talk about the correlation between stress and diet when it comes to IBS? 24:21
• How are we dealing with the ramifications of GLP-1s? 29:33
• As providers, what is your first instinct when patients tell you they started GLP-1s? 32:28
• How is the community going to help listeners weed through Internet noise to find accurate information? 35:01
• Group discussion on the rise of severe constipation. 41:31
• Who decides to send patients for colectomy consultations? 43:33
• Is there anything else you want to share or highlight from the conference? 47:25
• Thank you all 48:58
• Thanks for listening 49:42

Erica Dermer is an IBS and Celiac Disease patient who hosts the Celiac and the Beast blog and You Had Me at Eat podcast series.

Amanda Lynett MS, RDN, is a registered dietitian with her masters. Amanda is with the Division of Gastroenterology at Michigan Medical in Ann Arbor.

Jeffrey Roberts, MSEd, BSc, is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS.

Kate Scarlata, MPH, RDN, is a US-based dietitian with over 30 years of experience. Kate’s expertise is in gastrointestinal disorders and food intolerance.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more Tuesday Night IBS, be sure check out TuesdayNightIBS.com and to follow and subscribe to their podcast.

Disclosures: Chey and Roberts report no relevant financial disclosures. Scarlata reports stock options with Epicured LLC and FODY Food Company, financial support from Dr. Schar, Mahana Therapeutics, Nestle Health Science, Olipop, Pendulum, QOL Medical.

In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more.

• Intro :58
• The interview/about Regueiro 1:03
• Tell us about your family and where you grew up. 1:24
• How did you get interested in medicine? 2:16
• Who were your early influences? 4:18
• What is the medical home? 5:57
• How did you develop the idea to apply the medical home model to IBD? 7:45
• Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57
• Why hasn’t this model become standard of care for patients with complex IBD? 14:13
• What has worked, and what hasn’t worked when it comes to adopting an integrative care medical home model? 18:15
• Are there themes patients share as to why they wouldn’t want to be enrolled in a medical home? 21:28
• What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09
• What have you learned in this position at Cleveland Clinic? 25:23
• Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34
• How would you recommend that people prepare for having a position like this? 27:34
• Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02
• With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06
• What are the challenges that you still see in the ways we are using telehealth? 39:05
• What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26
• Thank you, Miguel 42:55
• Thanks for listening 45:11

Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X.

Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more.

• Intro :24
• The interview/about Stidham :36
• Tell us about your family and where you grew up. 1:14
• How did you embrace changes in technology growing up? 3:07
• What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator? 6:05
• What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32
• Can you give a quick overview of what these tools and technologies entail? 12:52
• What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12
• Where did your interest in AI come about? 20:26
• You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58
• How do we change the way we train GI doctors, and should we start making these changes today? 26:38
• With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33
• What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06
• What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39
• Thank you, Ryan 44:04
• Thanks for listening 44:20

Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.

We’d love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X.

Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.